

ONLINE SUPPLEMENTARY DATA


Supplementary Table 1. SLE patient demographics and Lectin Pathway protein measurements at the two Danish inclusion sites.

Danish cohorts: Aarhus vs. Odense		
	Aarhus	Odense
<i>Patient number</i>	169	203
<i>Age at inclusion, mean (sd)</i>	45.4 (14.9)	47.8 (14.3)
<i>Age at diagnosis, mean (sd)</i>	33.5	35.9
<i>Gender F (%)</i>	90	86
<i>Ethnicity: Caucasian (%)</i>	97	97
ACR criteria (cumulative)		
<i>Number of ACR criterias, mean (sd)</i>	6.3 (1.2)	5.6 (1.6)
<i>Malar rash (ACR1) (%)</i>	65.7	50.7
<i>Discoid lupus (ACR2) (%)</i>	5.3	5.4
<i>Photosensitivity (ACR3) (%)</i>	67.5	59.2
<i>Oral/nasal ulcers (ACR4) (%)</i>	44.4	23.8
<i>Arthritis (ACR5) (%)</i>	91.7	86.2
<i>Serositis (ACR6) (%)</i>	34.9	42.6
<i>Nephritis (ACR7) (%)</i>	31.4	36.0
<i>CNS (ACR8) (%)</i>	8.4	16.3
<i>Hematological (ACR9) (%)</i>	89.9	55.7
<i>Immunological (ACR10) (%)</i>	90.5	85.7
<i>ANA (ACR11) (%)</i>	98.2	100
Clinical and biochemical data at time of inclusion		
<i>SLEDAI at inclusion, mean (sd)</i>	3.9 (3.3)	2.5 (2.7)
<i>SLICC, mean (sd)</i>	0.9 (1.2)	1.7 (2.9)
Treatment at time of inclusion		
<i>Hydroxychloroquine treatment (%)</i>	79.6	48.8
<i>Prednisolone treatment (%)</i>	57.4	51.7
<i>Other immuno-suppressives (%)</i>	39.5	44.8
Lectin Pathway Proteins (median ng/ml)		
<i>MBL</i>	1776	1595
<i>M-ficolin</i>	2414	2349
<i>H-ficolin</i>	45195	43795
<i>CL-L1</i>	449	470
<i>CL-K1</i>	445	475
<i>MASP-1</i>	10621	10806
<i>MASP-3</i>	6977	7431
<i>MAp44</i>	2326	2482
<i>MASP-2</i>	492	583
<i>MAp19</i>	342	372


Supplementary Figure 1. Displays LP protein concentrations in SLE patients with and without kidney affection based on the ACR-7 criteria.

	<i>SLE patients with kidney affection (+ACR 7) (n=125)</i> Median serum conc. $\mu\text{g/ml}$ (range)	<i>SLE patients without kidney affection (-ACR 7) (n=240)</i> Median serum conc. $\mu\text{g/ml}$ (range)	<i>p-value</i>
<i>MBL</i>	1.794 (0 – 7.821)	1.286 (3 – 9.976)	0.074
<i>M-ficolin</i>	2.498 (0.642-7.297)	2.330 (0.528-6.991)	0.658
<i>L-ficolin*</i>	3.482 (0.714-10.377)	3.775 (0.338-8.833)	0.297
<i>H-ficolin</i>	48.79 (0.0-119.1)	42.16 (8.135-119.1)	0.604
<i>CL-L1</i>	0.466 (0.299-0.712)	0.466 (0.354-0.745)	0.664
<i>CL-K1</i>	0.499 (0.285-0.724)	0.521 (0.326-0.920)	0.026
<i>MASP-1</i>	10.39 (2.944-38.75)	10.99 (3.290-33.48)	0.483
<i>MASP-3</i>	7.011 (3.029-20.45)	7.482 (2.750-22.29)	0.045
<i>MApp44</i>	2.427 (1.141-5.941)	2.444 (1.053-8.674)	0.933
<i>MASP-2</i>	0.550 (0.065-3.612)	0.544 (0.100-2.698)	0.966
<i>MApp19</i>	0.369 (0.050-0.990)	0.367 (0.070-0.825)	0.223

Supplementary Figure 2. Complement proteins and markers of inflammation. Fig. 2a-b. illustrates association between C3 and C4 and C3 and CRP. Fig. 2c-f. shows M-ficolin correlation to both C3, CRP, leucocytes and neutrophils.



Supplementary Figure 3. Treatment effect on LP protein concentrations. Sup. fig 1a-k. Lectin pathway protein concentrations in 372 Danish SLE patients receiving different treatment modalities.



Supplementary Figure 4. Average SLEDAI and average LP protein concentration (with 95 % CI) at each sampling year for Swiss patients followed over time. The figure illustrates the influence of time as well as disease activity on protein concentrations.

